LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

37.02 2.89

Buy Sell

Overview

Share price change

24h

Current

Min

36.12

Max

37.05

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	11.202 80.03
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+27.74% upside

Market Stats
By TradingEconomics
Market Cap	358M 2B
Previous open	34.13
Previous close	37.02

News Sentiment

By Acuity

44%

56%

144 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Dec 2025, 23:21 UTC

Earnings

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 Dec 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 Dec 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

3 Dec 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 Dec 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 Dec 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 Dec 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 Dec 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 Dec 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 Dec 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 Dec 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 Dec 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 Dec 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 Dec 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

3 Dec 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 Dec 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 Dec 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 Dec 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 Dec 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Dec 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 Dec 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 Dec 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

27.74% upside

12 Months Forecast

Average 46 USD 27.74%

High 62 USD

Low 32 USD

Based on 10 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

144 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.